Powers Advisory Group’s GSK GSK Stock Holding History

Powers Advisory Group’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Sell	4,800 -384	-7%	-$20.3K	0.08%	123
2026 Q1	$286K	Buy	5,184 +1	+0%	+$54	0.1%	107
2025 Q4	$254K	Buy	5,183 +1	+0%	+$47	0.1%	112
2025 Q3	$224K	Buy	+5,182	New	+$202K	0.09%	116
2024 Q2	–	Sell	-4,850	Closed	-$208K	–	97
2024 Q1	$208K	Sell	4,850 -1,081	-18%	-$44.6K	0.12%	93
2023 Q4	$220K	Sell	5,931 -295	-5%	-$10.6K	0.14%	90
2023 Q3	$226K	Hold	6,226	–	–	0.15%	84
2023 Q2	$222K	Sell	6,226 -321	-5%	-$11.5K	0.15%	87
2023 Q1	$233K	Hold	6,547	–	–	0.16%	88
2022 Q4	$230K	Buy	+6,547	New	+$218K	0.17%	85
2022 Q3	–	Sell	-7,015	Closed	-$382K	–	93
2022 Q2	$382K	Sell	7,015 -291	-4%	-$16.1K	0.29%	69
2022 Q1	$398K	Buy	7,306 +51	+0.7%	+$2.77K	0.28%	72
2021 Q4	$400K	Buy	+7,255	New	+$377K	0.28%	70

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Powers Advisory Group's GSK Position: Q2 2026 in Review

Powers Advisory Group reduced its GSK (GSK) stake by 7.4% in Q2 2026, selling an estimated $20.3K and leaving 4,800 shares worth $252K. The position accounts for 0.08% of the portfolio, ranked #123.

Powers Advisory Group first reported a position in GSK in Q4 2021 and has held it in 13 quarters since. The position peaked at $400K in Q4 2021. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Powers Advisory Group held 4,800 shares of GSK worth $252K as of Q2 2026.
Powers Advisory Group sold 384 GSK shares in Q2 2026, an estimated $20.3K.
GSK made up 0.08% of Powers Advisory Group's portfolio in Q2 2026, its #123 holding.
Powers Advisory Group first reported a position in GSK in Q4 2021 and has held it in 13 quarters since.
Powers Advisory Group's GSK position peaked at $400K in Q4 2021.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Powers Advisory Group's 13F filing for Q2 2026, filed 31 Jul 2026.